Author:
Lipson Evan J.,Forde Patrick M.,Hammers Hans-Joerg,Emens Leisha A.,Taube Janis M.,Topalian Suzanne L.
Reference70 articles.
1. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2010
2. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody;Lipson;Clin Cancer Res,2013
3. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012
4. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab;Topalian;J Clin Oncol,2014
5. Long-term survival of ipilimumab-naïve patients with advanced melanoma treated with nivolumab in a phase 1 trial [abstract];Hodi;Pigment Cell Melanoma Res (Meeting Abstracts),2014
Cited by
265 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献